Colorectal cancer

This phase 2 trial is testing whether adding an experimental drug called evorpacept to two existing cancer drugs (cetuximab and pembrolizumab) can shrink tumors in people with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study enro…

This early-phase trial tests a personalized cell therapy called TCR-T cells, engineered to recognize and attack cancer cells with a specific KRAS mutation. Up to 18 adults with advanced pancreatic cancer who have exhausted standard treatments will receive a single infusion of the…

This phase 2 trial tests whether adding panitumumab to standard chemotherapy can shrink tumors in people with metastatic colorectal cancer that has low-frequency RAS mutations. The idea is that even if a small number of cancer cells have the mutation, most cells may still respond…

This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…

This clinical trial is testing whether a combination of two immunotherapy drugs, relatlimab and nivolumab, can help people with advanced colorectal cancer that has not responded to previous treatments. The study compares this combination to two standard chemotherapy options (rego…

This phase 2 trial tests two different drug combinations as a first treatment for people with metastatic colorectal cancer—cancer that has spread beyond the colon or rectum. Participants receive capecitabine (Xeloda) plus bevacizumab (Avastin), and are randomly assigned to also g…

This trial is testing whether combining an experimental oral drug called IBI351 with the IV drug cetuximab can shrink tumors in people with metastatic colorectal cancer that has a specific KRAS G12C mutation. The study starts with a small group to find the safest dose, then compa…

This trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…

This trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…

This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…

This early-phase study tests a portable device that sends gentle electric fields to the liver, combined with chemotherapy and a targeted drug (bevacizumab), in people whose cancer has spread to the liver and stopped responding to standard treatments. The main goal is to find the …

This Phase 3 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can help people with advanced colorectal cancer that can't be removed by surgery and has stopped responding to chemotherapy. About 834 participants will receive either th…

This trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…

This early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…

This early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…

This trial tested a vaccine called PD1-Vaxx given before surgery to people with a specific type of colorectal cancer (MSI-high). The goal was to see if the vaccine could shrink tumors, measured by how many cancer cells remained after treatment. Only 3 people took part, and the st…

This study tests whether adding hydroxychloroquine (a drug used for malaria) to standard targeted therapy can help shrink tumors in people with advanced colorectal cancer that has a specific BRAF mutation and has stopped responding to prior treatments. The trial enrolled 7 adults…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This early-stage study tested a new drug called PF-07284892, alone or with other medicines, in people with advanced solid tumors that had specific genetic changes. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited…

This early-stage study tested a new cancer pill (PF-07985045) alone or with other drugs in people with advanced solid tumors that have a KRAS gene mutation. The trial included patients with lung, colon, or pancreatic cancer. The study aimed to check safety and find the right dose…

This early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…

This study tested a drug called BM7PE immunotoxin in 14 people with colorectal cancer that had spread and was no longer responding to standard chemotherapy. The goal was to find a safe dose and see if it could help patients live longer. The study was stopped early, so we have lim…

This study tested a treatment called radioembolization for elderly or frail patients whose colorectal cancer has spread only to the liver and cannot be removed by surgery. Instead of standard chemotherapy, tiny radioactive beads are injected into the liver's blood supply to targe…

This phase 3 trial tested a drug called A140 (similar to cetuximab) combined with chemotherapy (mFOLFOX6) as a first treatment for people with a specific type of advanced colorectal cancer (RAS wild-type). The study planned to enroll 570 people in China but was terminated early w…

This study tested whether drinking a mix of branched-chain amino acids (BCAAs) a few hours before colorectal cancer surgery could help prevent high blood sugar afterward. About 79 patients were split into two groups: one got a BCAA drink, the other plain water. The goal was to se…

This study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…

This study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 peopl…

This phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…

This study tested a combination of two drugs, VB-111 and nivolumab, in 14 adults with colorectal cancer that had spread to the liver. The goal was to see if the treatment was safe and could shrink tumors. The trial was terminated early, but researchers collected data on side effe…

This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This phase 2 trial tested a combination of three drugs—nivolumab (an immunotherapy), tadalafil (commonly used for erectile dysfunction), and vancomycin (an antibiotic)—in adults with liver cancer or liver metastases from colorectal or pancreatic cancers that had not responded to …

This study tested whether adding the experimental drug ompenaclid to standard chemotherapy could shrink tumors in people with advanced colorectal cancer that has a RAS gene mutation. About 76 participants were randomly assigned to receive either ompenaclid or a placebo, along wit…

This study looked at whether removing liver tumors with surgery, along with chemotherapy, helps people with colorectal cancer that has spread to the liver and lungs live longer compared to chemotherapy alone. The trial was stopped early after enrolling only 29 participants. The r…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…

This early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells in the gut. The study included 17 adults with advanced colorectal, stomach, pancreatic, or small bowel …

This early-stage study tested whether adding curcumin (a compound in turmeric) to standard chemotherapy could help patients with metastatic colon cancer that no longer responds to 5FU. The goal was to check safety and see if the combination shrinks tumors. Only 15 people were enr…

This study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early a…

This study tested whether a special CT scan that highlights blood flow (porto-scanner with Angio-CT) helps doctors more accurately destroy small liver tumors from colorectal cancer using heat ablation, compared to a standard CT scan. The goal was to see if the new method leads to…

This early-phase trial tested a gene therapy approach for metastatic cancer that produces a protein called CEA. Researchers took white blood cells from patients, added a gene to help them target CEA, and infused them back along with chemotherapy and a drug called IL-2. Only 3 peo…

This study tested a combination of two drugs (regorafenib and pembrolizumab) for people with a specific type of advanced colorectal cancer called MSI-H. The goal was to see if the combination worked better than pembrolizumab alone. The trial was stopped early after enrolling only…

This early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …

This phase 2 study tested a two-step treatment for colorectal cancer that had spread only to the liver and could not be removed by surgery. First, patients received radioactive beads (Holmium-166 TARE) directly into the liver, followed by maintenance chemotherapy and targeted dru…

This study tested two drugs, pembrolizumab and vactosertib, given before and after surgery to remove liver tumors in people with colorectal cancer that had spread to the liver. The goal was to see if these drugs could shrink the liver tumors before surgery and lower the chance of…

This early-phase study tested several drug combinations in 122 adults with advanced or metastatic BRAF V600 colorectal cancer. The goal was to find safe doses and understand side effects. The trial was terminated, so final results are not available.

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…

This early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find…

This study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …

This study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …

This early-phase study tested an experimental drug called AMG 199 in adults with advanced stomach, gastroesophageal junction, colorectal, or pancreatic cancers that have a specific protein (MUC17). The main goals were to check safety and find the best dose. The study was stopped …

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…

This phase 2 trial tested a combination of a therapeutic vaccine (EO2040) and an immunotherapy drug (nivolumab) in colorectal cancer patients who had minimal residual disease detected by a blood test after completing standard treatment. The goal was to clear remaining cancer cell…

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…

This early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …

This early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…

This phase 2 trial tested a new drug combination (NUFIRI-bev) against the standard treatment (FOLFIRI-bev) in 171 people with metastatic colorectal cancer that had already been treated. The goal was to see if the new combo could delay cancer growth better than the standard. Howev…

This early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …

This study compared two different contrast agents used in liver MRI scans to see if a shorter, cheaper scan could work as well as the standard one for finding colorectal cancer that has spread to the liver. The trial planned to enroll 10 adults with suspected liver metastases, bu…

This pilot study tested a blood-based test (Harbinger test) to help decide who needs a colonoscopy after a positive colorectal cancer screening. The goal was to see if the blood test could accurately predict colorectal cancer or advanced adenomas. However, the study was terminate…

This early study tested a special dye called VGT-309 that makes cancer cells glow during a colonoscopy. The goal was to see if it is safe and helps doctors find colorectal tumors more easily. The study was stopped early and included 9 adults with colorectal cancer.

This early-phase study tested whether special PET scans using glutamine and FSPG can better detect tumors in people with advanced colorectal cancer. Six participants received these imaging agents, and researchers compared the results to standard CT or MRI scans. The study was ter…

This Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…

This study tested whether a web-based symptom tracking tool could improve quality of life for people with early-stage breast or colorectal cancer receiving chemotherapy. Participants were randomly assigned to either use the online tool to report symptoms between clinic visits or …

This study tests whether a moderate-to-vigorous exercise program can change the gut bacteria of people who have survived stage II or III colorectal cancer. Researchers will enroll 30 survivors and randomly assign them to either an exercise group or a health education group. The m…

This study surveys colorectal cancer patients about their use of complementary and alternative medicines (CAM), such as acupuncture, homeopathy, or dietary supplements. Researchers aim to understand which patients use CAM, why, and how it might affect their quality of life and ca…

This study aimed to find inherited gene changes in people diagnosed with cancer at a young age, including breast, ovarian, colorectal, and pediatric cancers. Researchers used a special test to look at 200 genes linked to cancer in 289 participants. The goal was to better understa…

This study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…

This study looked at how radiofrequency ablation (RFA), a procedure that uses heat to destroy tumors, affects the immune system in people with lung metastases from colorectal cancer. Researchers measured immune cells in tumor samples and blood before and after RFA in 20 participa…

This study looked at tiny particles called exosomes in the blood of 172 colorectal cancer patients. Researchers wanted to see if the contents of these particles could help predict survival and cancer spread. The goal was to find new biomarkers that could be measured with a simple…

This study followed 28 adults with liver, colorectal, melanoma, or kidney cancers who received high-dose radiation therapy. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to learn how the immune system…

This study aimed to see if a CT scan of the colon (CT-colonography) is more acceptable than a standard colonoscopy for people at high risk of colorectal cancer. It included 39 patients with a personal or family history of advanced polyps or cancer. The main goal was to measure ho…

This study aimed to see if a simple blood test (liquid biopsy) could help doctors make better treatment decisions for people with advanced cancers of the colon, pancreas, or bile duct. Researchers planned to enroll about 130 participants but stopped early with only 16 enrolled. T…

This study aimed to see if a short video explaining different colorectal cancer screening options (like colonoscopy, FIT, and Cologuard) could help more people get screened. It included 1,823 adults aged 45-70 who had never been screened. However, the study was stopped early and …

This observational registry aims to learn about the health, wellbeing, and needs of people who were diagnosed with cancer between ages 18 and 39. Participants complete surveys every 6 to 12 months about anxiety, depression, social support, and financial distress. The registry als…